Pharma Stocks Surge Against Market Dip as Government Promises New Support Scheme for Bulk Drug Industry

Pharma Stocks Surge Against Market Dip as Government Promises New Support Scheme for Bulk Drug Industry​

Pharma Sector Outperforms Broader Markets Amid Policy Assurance​

The Nifty Pharma index maintained strength on June 8, trading 0.3% higher despite broader market pressures that led to selling in other sectors. This resilient performance is primarily attributed to assurances from the pharmaceutical secretary regarding forthcoming government support for the bulk drugs industry.

Pharmaceutical companies are showing sustained investor confidence as the Ministry focuses on long-term stability rather than short-term relief measures. Companies like Alkem Laboratories and Ajanta Pharma rose strongly, with both trading up 2.1% and 1.24%, respectively. Meanwhile, Max Healthcare and Apollo Hospitals were among the top gainers within the Nifty index segment.

Government Proposes Comprehensive Support Beyond Incentives​

Manoj Joshi, the pharmaceutical secretary, confirmed in an interview that the government is actively developing a new scheme to bolster the bulk drugs industry. This initiative will move past simple production-linked incentives.

The proposed plan aims for long-term capacity creation and establishing stronger links between academia and industry research and development (R&D). Joshi stated that the future scheme would provide flexibility, allowing more time for the industry to set up new units and offering flexible support for product R&D.

Managing Input Costs and Supply Chain Resilience​

The pharma industry has faced significant challenges regarding raw material costs. For certain medicines, raw material costs have seen increases ranging from 20% to 30%. However, the sector has managed to absorb these cost increases thus far.

Secretary Joshi clarified that the Centre is not considering a universal emergency hike across all medicine prices. Nonetheless, he added that individual cases demonstrating exceptional input-cost inflation are currently being closely examined by relevant authorities.

Stability Reached in Critical Raw Material Supplies​

India's pharmaceutical sector has demonstrated considerable resilience despite disruptions caused by geopolitical tensions in West Asia. Initial shortages of certain active pharmaceutical ingredients (APIs) and solvents have since stabilized within the market.

Critical input supplies, including methanol, ammonia, and propylene, which are essential for manufacturing isopropyl alcohol and various pharma products, have normalized completely. Despite this stability, elevated crude and petrochemical prices continue to exert pressure on costs related to transport, packaging, and manufacturing across the industry.